

Comparative effectiveness of extended-release naltrexone
for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Lancet, The

391, 309-318

DOI: [10.1016/s0140-6736\(17\)32812-x](https://doi.org/10.1016/s0140-6736(17)32812-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Narrowing the treatment gap in managing opioid use disorder. <i>Cmaj</i> , 2018, 190, E236-E237.	2.0	6
2	Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. <i>Addiction</i> , 2018, 113, 1477-1487.	3.3	21
3	Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 43-53.	2.1	72
4	Extended-release injectable naltrexone for opioid use disorder: a systematic review. <i>Addiction</i> , 2018, 113, 1188-1209.	3.3	148
5	Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 31-33.	2.8	1
6	Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough. <i>CNS Spectrums</i> , 2018, 23, 113-116.	1.2	0
7	Commentary: Providing technical assistance for the state targeted response for opioid use disorders: Time is of the essence. <i>American Journal on Addictions</i> , 2018, 27, 158-160.	1.4	2
8	Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. <i>Drug and Alcohol Dependence</i> , 2018, 187, 171-178.	3.2	35
9	Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. <i>American Journal on Addictions</i> , 2018, 27, 177-187.	1.4	38
10	Perceptions and practices addressing diversion among US buprenorphine prescribers. <i>Drug and Alcohol Dependence</i> , 2018, 186, 147-153.	3.2	38
11	Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. <i>Drug Safety</i> , 2018, 41, 981-988.	3.2	25
12	Frontiers in Opioid Pharmacology. <i>Anesthesiology</i> , 2018, 128, 865-866.	2.5	0
13	Extended-release naltrexone: good but not a panacea. <i>Lancet, The</i> , 2018, 391, 283-284.	13.7	7
14	A Nurse Practitioner's Perspective on Prescribing Suboxone for Opioid Use Disorder. <i>Journal of Addictions Nursing</i> , 2018, 29, 226-229.	0.4	2
15	Pregnancy and Naltrexone Pharmacotherapy. <i>Obstetrics and Gynecology</i> , 2018, 132, 923-925.	2.4	9
16	Addressing the Opioid Public Health Crisis. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 6s-7s.	0.8	0
17	Pharmacotherapy for opioid addiction in community corrections. <i>International Review of Psychiatry</i> , 2018, 30, 117-135.	2.8	8
18	The Cholinergic System as a Treatment Target for Opioid Use Disorder. <i>CNS Drugs</i> , 2018, 32, 981-996.	5.9	22

#	ARTICLE	IF	CITATIONS
19	Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. <i>American Journal on Addictions</i> , 2018, 27, 612-617.	1.4	87
20	Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2018, 192, 264-270.	3.2	62
21	Utilizing resources of neuropsychopharmacology to address the opioid overdose crisis. <i>Neuropsychopharmacology Reports</i> , 2018, 38, 100-104.	2.3	2
22	Attentional bias in opioid users: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2018, 191, 270-278.	3.2	30
23	Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. <i>Addiction</i> , 2018, 113, 1840-1849.	3.3	20
24	Where's Our Lin Zexu? A Call for Leadership and Resources to Address the Opioid Epidemic. <i>American Journal of Psychiatry</i> , 2018, 175, 495-497.	7.2	0
25	DARK Classics in Chemical Neuroscience: Morphine. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2395-2407.	3.5	60
26	Reducing Harm from Opioids: New Approaches for a Pressing Problem. <i>Anesthesiology</i> , 2018, 128, A19-A19.	2.5	0
27	Office-Based Addiction Treatment in Primary Care. <i>Medical Clinics of North America</i> , 2018, 102, 635-652.	2.5	17
28	A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. <i>PLoS ONE</i> , 2018, 13, e0199951.	2.5	11
29	Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence". <i>Drug Safety</i> , 2018, 41, 991-993.	3.2	2
30	Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence". <i>Drug Safety</i> , 2018, 41, 995-997.	3.2	0
31	Italian psychiatry. <i>International Review of Psychiatry</i> , 2018, 30, 117-117.	2.8	1
32	Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. <i>Drug Safety</i> , 2018, 41, 979-980.	3.2	9
33	Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. <i>American Journal on Addictions</i> , 2018, 27, 471-476.	1.4	4
34	Extended-release naltrexone overlooked in opioid use disorders guideline. <i>Cmaj</i> , 2018, 190, E862-E862.	2.0	1
35	Overdose Prevention Through Medical Treatment of Opioid Use Disorders. <i>Annals of Internal Medicine</i> , 2018, 169, 190.	3.9	39
36	Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy. <i>Anesthesiology Clinics</i> , 2018, 36, 345-359.	1.4	52

#	ARTICLE	IF	CITATIONS
37	Comparison between buprenorphine provider availability and opioid deaths among US counties. <i>Journal of Substance Abuse Treatment</i> , 2018, 93, 19-25.	2.8	50
38	Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. <i>Journal of Substance Abuse Treatment</i> , 2018, 91, 1-11.	2.8	14
39	Treatment Approaches for Opioid Use Disorders in Late Life. <i>Current Treatment Options in Psychiatry</i> , 2018, 5, 242-254.	1.9	0
40	Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. <i>Addictive Behaviors</i> , 2018, 86, 111-117.	3.0	62
41	Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. <i>American Journal on Addictions</i> , 2018, 27, 465-470.	1.4	40
42	Adherence to extended release naltrexone: Patient and treatment characteristics. <i>American Journal on Addictions</i> , 2018, 27, 524-530.	1.4	8
43	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. <i>Annals of Internal Medicine</i> , 2018, 169, 137.	3.9	680
44	Developing an opioid use disorder treatment cascade: A review of quality measures. <i>Journal of Substance Abuse Treatment</i> , 2018, 91, 57-68.	2.8	114
45	Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. <i>American Journal of Preventive Medicine</i> , 2018, 54, S230-S242.	3.0	177
46	Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment. <i>Current HIV/AIDS Reports</i> , 2018, 15, 315-323.	3.1	25
47	Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2019, 24, 1868-1883.	7.9	215
48	Vaccine blunts fentanyl potency in male rhesus monkeys. <i>Neuropharmacology</i> , 2019, 158, 107730.	4.1	41
49	Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 34-41.	2.8	3
50	<i>Drug Policy and the Public Good</i>: a summary of the second edition. <i>Addiction</i> , 2019, 114, 1941-1950.	3.3	7
52	Circumstances of death of opioid users being treated with naltrexone. <i>Addiction</i> , 2019, 114, 2000-2007.	3.3	6
53	Provider-directed marketing may increase prescribing of medications for opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 104-115.	2.8	8
54	Translating Neurobiology into Practice in Tobacco, Alcohol, Drug, and Behavioral Addictions. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 389-401.	0.7	0
55	The Changing Landscape of Substance Use Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 152-153.	0.8	0

#	ARTICLE	IF	CITATIONS
56	Court personnel attitudes towards medication-assisted treatment: A state-wide survey. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 72-82.	2.8	37
57	Current status of opioid addiction treatment and related preclinical research. <i>Science Advances</i> , 2019, 5, eaax9140.	10.3	60
58	Perspectives on the HIV continuum of care among adult opioid users in New York City: a qualitative study. <i>Harm Reduction Journal</i> , 2019, 16, 58.	3.2	12
60	Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107649.	3.2	14
61	Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 422-452.	2.5	39
62	A 3â€™ UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction. <i>PLoS ONE</i> , 2019, 14, e0224399.	2.5	8
63	Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study. <i>Substance Abuse and Rehabilitation</i> , 2019, Volume 10, 57-67.	4.8	6
64	The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. <i>Translational Psychiatry</i> , 2019, 9, 282.	4.8	107
65	Physiciansâ€™ satisfaction with providing buprenorphine treatment. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 34.	2.6	9
66	Treatment of Opioid Use Disorder in Pediatric Medical Settings. <i>Current Addiction Reports</i> , 2019, 6, 374-382.	3.4	4
67	Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. <i>Molecular Psychiatry</i> , 2019, 24, 1779-1786.	7.9	100
68	Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care. <i>Substance Use and Misuse</i> , 2019, 54, 2409-2419.	1.4	40
69	Medication-Assisted Treatment for Opioid-Use Disorder. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2072-2086.	3.0	75
70	What place for prolonged-release buprenorphine depot-formulation BuvidalÂ® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 907-914.	5.0	25
71	Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. <i>Clinical Psychological Science</i> , 2019, 7, 1190-1206.	4.0	36
72	Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107501.	3.2	20
73	Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 37.	2.6	36
74	Article Commentary: Underutilization of Medications to Treat Opioid use Disorder: What Role does Stigma Play?. <i>Substance Abuse</i> , 2019, 40, 459-465.	2.3	55

#	ARTICLE	IF	CITATIONS
75	Substance Use Disorder, Intravenous Injection, and HIV Infection: A Review. <i>Cell Transplantation</i> , 2019, 28, 1465-1471.	2.5	18
76	Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential. <i>CNS Drugs</i> , 2019, 33, 1147-1154.	5.9	18
77	Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. <i>Journal of Substance Abuse Treatment</i> , 2019, 99, 32-43.	2.8	109
78	Criminal Justice Barriers to Treatment of Opioid Use Disorders in the United States: The Need for Public Health Advocacy. <i>American Journal of Public Health</i> , 2019, 109, 419-422.	2.7	27
79	Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 1-6.	3.1	48
80	Improving Our Understanding of Substance Use Disorders. <i>American Journal of Psychiatry</i> , 2019, 176, 87-89.	7.2	6
81	Pharmacological and Behavioral Treatment of Opioid Use Disorder. <i>Psychiatric Research and Clinical Practice</i> , 2019, 1, 4-15.	2.4	53
82	Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates. <i>American Journal on Addictions</i> , 2019, 28, 270-276.	1.4	13
83	Letter to the Editor: Training General Psychiatrists to Treat Patients with Substance Use Disorders: It is Time to Change the Training Requirements in Psychiatry Residency Training. <i>American Journal on Addictions</i> , 2019, 28, 150-152.	1.4	1
84	Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: Evidence from real world data. <i>Drug and Alcohol Dependence</i> , 2019, 201, 197-204.	3.2	12
85	A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 630-634.	0.9	2
86	Nowhere to go? Examining facility acceptance levels for serving individuals using medications for opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 42-50.	2.8	7
87	Buprenorphine Treatment for Opioid Use Disorder: An Overview. <i>CNS Drugs</i> , 2019, 33, 567-580.	5.9	86
88	The case for a medication first approach to the treatment of opioid use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 333-340.	2.1	41
89	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	3.2	113
90	Implementing access to medication assisted treatment in a drug treatment court: Correlates, consequences, and obstacles. <i>Journal of Offender Rehabilitation</i> , 2019, 58, 178-198.	0.8	13
91	Anxiety sensitivity and opioid misuse among opioid-using adults with chronic pain. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 470-478.	2.1	33
92	Opioid use disorder deaths and the effects of medication therapy. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 227-229.	2.1	1

#	ARTICLE	IF	CITATIONS
93	Potential uses of naltrexone in emergency department patients with opioid use disorder. <i>Clinical Toxicology</i> , 2019, 57, 753-759.	1.9	3
94	The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial. <i>Drug and Alcohol Dependence</i> , 2019, 197, 220-227.	3.2	16
95	Management of opioid use disorder in the USA: present status and future directions. <i>Lancet, The</i> , 2019, 393, 1760-1772.	13.7	277
96	Bifunctional opioid receptor ligands as novel analgesics. <i>Neuropharmacology</i> , 2019, 151, 195-207.	4.1	34
97	Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. <i>Lancet HIV</i> , 2019, 6, e221-e229.	4.7	13
98	News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic. <i>Health Affairs</i> , 2019, 38, 643-651.	5.2	37
99	A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions. <i>Drug and Alcohol Dependence</i> , 2019, 197, 168-182.	3.2	26
100	Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. <i>Annual Review of Biomedical Engineering</i> , 2019, 21, 61-84.	12.3	17
101	Medication-Assisted Treatment for Opioid Use Disorder in Older Adults: An Emerging Role for the Geriatric Psychiatrist. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 455-457.	1.2	13
102	Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 180-185.	2.1	8
103	Factors influencing recruitment to a randomised placebo-controlled trial of oral naltrexone and extended release implant naltrexone: Qualitative study. <i>Journal of Substance Abuse Treatment</i> , 2019, 99, 52-60.	2.8	7
104	Exploring anxiety sensitivity in the relationship between pain intensity and opioid misuse among opioid-using adults with chronic pain. <i>Journal of Psychiatric Research</i> , 2019, 111, 154-159.	3.1	25
105	One prescription for the opioid crisis: require buprenorphine waivers for pain medicine fellows. <i>Regional Anesthesia and Pain Medicine</i> , 2019, , rapm-2019-100743.	2.3	4
106	Medications for management of opioid use disorder. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1097-1103.	1.0	56
107	Clinical Trials for Opioid Use Disorder. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 167-202.	1.8	3
108	Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use. <i>Journal of Addiction Medicine</i> , 2019, 13, 300-305.	2.6	12
109	Article Commentary: Medicine, with a Focus on Physicians: Addressing Substance use in the 21st Century. <i>Substance Abuse</i> , 2019, 40, 396-404.	2.3	7
110	Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders. <i>Advances in Anesthesia</i> , 2019, 37, 65-86.	0.9	3

#	ARTICLE	IF	CITATIONS
111	HIV and Substance Use Disorder. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 835-855.	5.1	12
112	Differential adoption of opioid agonist treatments in detoxification and outpatient settings. <i>Journal of Substance Abuse Treatment</i> , 2019, 107, 24-28.	2.8	13
113	Opioid use disorder and treatment: challenges and opportunities. <i>BMC Health Services Research</i> , 2019, 19, 884.	2.2	42
114	Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. <i>BMC Health Services Research</i> , 2019, 19, 862.	2.2	26
115	Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence. <i>Journal of Addiction Medicine</i> , 2019, 13, 253-257.	2.6	27
116	False Positive Urine Drug Screens in Patients Receiving Oral Naltrexone. <i>Canadian Journal of Addiction</i> , 2019, 10, 25-26.	0.4	1
117	Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks. <i>Journal of Studies on Alcohol and Drugs</i> , 2019, 80, 393-402.	1.0	34
118	Cost-Effectiveness of Buprenorphine+Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. <i>Annals of Internal Medicine</i> , 2019, 170, 90.	3.9	50
119	State-of-The-Art Treatment of Opioid Use Disorder. , 2019, , 91-104.		0
120	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. <i>JAMA Psychiatry</i> , 2019, 76, 127.	11.0	44
121	Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. <i>Addiction</i> , 2019, 114, 1346-1353.	3.3	45
122	Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder. <i>Journal of the American Psychiatric Nurses Association</i> , 2019, 25, 272-279.	1.0	2
123	Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities. <i>Health Affairs</i> , 2019, 38, 14-23.	5.2	126
124	A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. <i>American Journal of Psychiatry</i> , 2019, 176, 129-137.	7.2	62
125	Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. <i>Neuropsychopharmacology</i> , 2019, 44, 259-273.	5.4	52
126	Extended-release injectable naltrexone (XR-NTX): a response to clinical issues raised by Brewer & Strel. <i>Addiction</i> , 2019, 114, 189-190.	3.3	1
127	Raja yoga meditation and medication-assisted treatment for relapse prevention: A pilot study. <i>Journal of Substance Abuse Treatment</i> , 2019, 96, 58-64.	2.8	9
128	Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 88-99.	2.5	28

#	ARTICLE	IF	CITATIONS
129	Prevention and Treatment of Opioid Misuse and Addiction. JAMA Psychiatry, 2019, 76, 208.	11.0	388
130	Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addiction Biology, 2020, 25, e12680.	2.6	30
131	Initiating buprenorphine treatment for opioid use disorder during short-term inpatient "detoxification": a randomized clinical trial. Addiction, 2020, 115, 82-94.	3.3	31
132	Emergency department-based peer support for opioid use disorder: Emergent functions and forms. Journal of Substance Abuse Treatment, 2020, 108, 82-87.	2.8	71
133	Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. Addiction, 2020, 115, 239-246.	3.3	17
134	Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. Journal of Substance Abuse Treatment, 2020, 108, 55-64.	2.8	32
135	Medication Treatment of Opioid Use Disorder. Biological Psychiatry, 2020, 87, 82-88.	1.3	165
136	Naltrexone use in pregnancy: a time for change. American Journal of Obstetrics and Gynecology, 2020, 222, 1-2.	1.3	18
137	Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder. Journal of Substance Abuse Treatment, 2020, 110, 49-58.	2.8	8
138	Opioid use disorder. Nature Reviews Disease Primers, 2020, 6, 3.	30.5	278
139	A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. American Journal of Drug and Alcohol Abuse, 2020, 46, 289-296.	2.1	7
140	The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders. Journal of Substance Abuse Treatment, 2020, 108, 33-39.	2.8	30
141	Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder. Drug and Alcohol Dependence, 2020, 207, 107799.	3.2	7
142	Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. International Journal of Drug Policy, 2020, 76, 102616.	3.3	58
143	Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug and Alcohol Dependence, 2020, 207, 107732.	3.2	55
144	Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder. Journal of Addiction Medicine, 2020, 14, e44-e52.	2.6	36
145	Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. Addiction, 2020, 115, 1413-1425.	3.3	17
146	Implementing Medication-Assisted Treatment for Opioid Use Disorder in Residential Programs. Addictive Disorders and Their Treatment, 2020, 19, 66-68.	0.5	0

#	ARTICLE	IF	CITATIONS
147	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	3.2	50
148	Mortality Among People With Opioid Use Disorder: A Systematic Review and Meta-analysis. <i>Journal of Addiction Medicine</i> , 2020, 14, e118-e132.	2.6	32
149	Age disparities in six-month treatment retention for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108130.	3.2	16
150	Case Study: Naltrexone for the Treatment of Nitrous Oxide Use. <i>Journal of Addiction Medicine</i> , 2020, 14, e277-e279.	2.6	5
151	Long-Term Efficacy of Medication-Assisted Treatment of Opioid Addiction: A Systematic Literature Review—Part 2. <i>Topics in Pain Management</i> , 2020, 35, 1-10.	0.0	0
152	Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual. <i>Journal of Addiction Medicine</i> , 2020, 14, 331-336.	2.6	10
153	A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2020, 119, 108146.	2.8	73
154	Longitudinal trends in nonmedical prescription opioid use in a cohort of rural Appalachian people who use drugs. <i>Preventive Medicine</i> , 2020, 140, 106194.	3.4	5
155	Precommitment Devices: A Defensible Treatment for Opioid Addiction?. <i>American Journal of Law and Medicine</i> , 2020, 46, 189-202.	0.2	1
156	Pharmacotherapy of Substance Use Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 330-333.	1.4	3
157	Medication Treatment and Health Care Use Among Adolescents With Opioid Use Disorder in Ohio. <i>Journal of Adolescent Health</i> , 2020, 67, 33-39.	2.5	13
158	A Virtual Standardized Patient–Based Assessment Tool to Evaluate Psychiatric Residents'™ Psychopharmacology Proficiency. <i>Academic Psychiatry</i> , 2020, 44, 693-700.	0.9	11
159	The role of the defense attorney in relation to biological interventions as rehabilitative strategies. <i>Journal of Offender Rehabilitation</i> , 2020, 59, 389-415.	0.8	1
160	Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. <i>Scientific Reports</i> , 2020, 10, 19471.	3.3	37
161	Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108221.	3.2	11
162	Management of Opioid Misuse and Opioid Use Disorders Among Youth. <i>Pediatrics</i> , 2020, 145, S153-S164.	2.1	19
163	Study protocol for a randomized controlled trial of mindfulness-based relapse prevention for opioid use disorders. <i>Contemporary Clinical Trials</i> , 2020, 99, 106182.	1.8	2
164	Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117149.	0.6	59

#	ARTICLE	IF	CITATIONS
165	Solving the Opioid Crisis Isn't Just a Public Health Challenge—It's a Bioethics Challenge. <i>Hastings Center Report</i> , 2020, 50, 24-32.	1.0	2
166	Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter. <i>Journal of Addictive Diseases</i> , 2020, 39, 37-45.	1.3	16
167	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 761-768.	2.1	3
168	A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 69.	2.2	27
169	Present and Future Pharmacological Treatments for Opioid Addiction. , 2020, , .		0
170	Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date. <i>Drugs</i> , 2020, 80, 1509-1524.	10.9	4
171	Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3661-e3669.	5.8	33
172	Implementation of strength-based case management for opioid-dependent patients presenting in medical emergency departments: rationale and study design of a randomized trial. <i>Trials</i> , 2020, 21, 761.	1.6	6
173	Risk Factors for Treatment Drop-Out: Implications for Adverse Outcomes When Treating Opioid Use Disorder. <i>Journal of Social Work Practice in the Addictions</i> , 2020, 20, 292-301.	0.7	3
174	Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder. <i>Journal of Adolescent Health</i> , 2020, 67, 778-785.	2.5	20
175	Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use—Associated Infective Endocarditis. <i>JAMA Network Open</i> , 2020, 3, e2016228.	5.9	65
176	The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. <i>Journal of Addiction Medicine</i> , 2020, 14, 1-91.	2.6	140
177	The relationship between incarceration history and overdose in North America: A scoping review of the evidence. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108088.	3.2	58
178	Individual and county-level variation in outcomes following non-fatal opioid-involved overdose. <i>Journal of Epidemiology and Community Health</i> , 2020, 74, 369-376.	3.7	16
179	New directions in the treatment of opioid withdrawal. <i>Lancet, The</i> , 2020, 395, 1938-1948.	13.7	72
180	Buprenorphine Treatment for Opioid Use Disorder in Community-Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results. <i>American Journal on Addictions</i> , 2020, 29, 271-278.	1.4	3
182	Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 68-75.	2.8	14
183	Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 266-272.	2.1	6

#	ARTICLE	IF	CITATIONS
184	Green Hope: Perspectives on Cannabis from People who Use Opioids. <i>Sociological Inquiry</i> , 2021, 91, 668-695.	2.0	3
185	Nicotine and Opioids: a Call for Co-treatment as the Standard of Care. <i>Journal of Behavioral Health Services and Research</i> , 2020, 47, 601-613.	1.4	17
186	Endogenous Opiates and Behavior: 2018. <i>Peptides</i> , 2020, 132, 170348.	2.4	19
187	Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults. <i>Addictive Behaviors</i> , 2020, 110, 106514.	3.0	5
188	Association between mortality rates and medication and residential treatment after inpatient medically managed opioid withdrawal: a cohort analysis. <i>Addiction</i> , 2020, 115, 1496-1508.	3.3	36
189	Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107848.	3.2	29
190	Medication-assisted therapies for opioid use disorders in patients with chronic pain. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116728.	0.6	4
191	Discontinuing Buprenorphine Treatment of Opioid Use Disorder: What Do We (Not) Know?. <i>American Journal of Psychiatry</i> , 2020, 177, 104-106.	7.2	11
192	Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 1-7.	2.0	19
193	Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. <i>JAMA Network Open</i> , 2020, 3, e1920622.	5.9	505
194	A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?. <i>American Journal on Addictions</i> , 2020, 29, 249-267.	1.4	18
195	Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality. <i>CNS Drugs</i> , 2020, 34, 629-642.	5.9	7
196	Validation of Addiction Severity Index (ASI) for Assessment of Psychiatric Comorbidity in Multi-Site Randomized Controlled Trials. <i>Journal of Dual Diagnosis</i> , 2020, 16, 312-321.	1.2	5
197	Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. <i>American Journal on Addictions</i> , 2020, 29, 313-322.	1.4	6
198	Diagnosis and Treatment of Opioid Use Disorder in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2082.	7.4	24
199	Classics in Chemical Neuroscience: Buprenorphine. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1385-1399.	3.5	7
200	Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 41-48.	2.8	34
201	Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 18-27.	2.8	7

#	ARTICLE	IF	CITATIONS
202	The changing opioid crisis: development, challenges and opportunities. <i>Molecular Psychiatry</i> , 2021, 26, 218-233.	7.9	197
203	Economic Evaluation in Opioid Modeling: Systematic Review. <i>Value in Health</i> , 2021, 24, 158-173.	0.3	14
204	Should Patients With Opioid Addiction Have a Second Valve Replacement for Endocarditis?. <i>Annals of Thoracic Surgery</i> , 2021, 111, 401-406.	1.3	6
205	Opioids and the Criminal Justice System: New Challenges Posed by the Modern Opioid Epidemic. <i>Annual Review of Criminology</i> , 2021, 4, 353-375.	3.5	15
206	A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder. <i>Addiction</i> , 2021, 116, 548-557.	3.3	21
207	Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study. <i>International Journal of Drug Policy</i> , 2021, 91, 102841.	3.3	12
208	Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, 62, 243-247.	0.4	11
209	Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?. <i>Journal of Substance Abuse Treatment</i> , 2021, 122, 108196.	2.8	39
210	The opioid epidemic: Mobilizing an academic health center to improve outcomes. <i>Journal of Substance Abuse Treatment</i> , 2021, 121, 108199.	2.8	2
211	An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108422.	3.2	3
212	Adapting treatment length to opioid-dependent individuals'™ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. <i>Addiction</i> , 2021, 116, 2084.	3.3	5
213	Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018. <i>Drug Safety</i> , 2021, 44, 351-359.	3.2	6
214	Commentary on Farnum et al .: Agonist maintenance in Ukraine"ambivalence, success and moving forward. <i>Addiction</i> , 2021, 116, 94-95.	3.3	0
215	Opioid use disorder and endocarditis. , 2021, , 125-160.		0
216	Inpatient opioid use disorder treatment for the infectious disease physician. , 2021, , 189-221.		0
217	Treating Opioid Use Disorder in Correctional Settings. , 2021, , 77-90.		1
218	Principles of Integrating Opioid Use Disorder Treatment in Primary Care. , 2021, , 23-42.		0
219	Reachable Moment: Hospital-Based Interventions. , 2021, , 43-56.		2

#	ARTICLE	IF	CITATIONS
220	Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables. <i>Addiction</i> , 2021, 116, 2094-2103.	3.3	4
221	Anxiety and Opioid Use Disorder: Potential Targets for Treatment and Prevention. <i>Current Addiction Reports</i> , 2021, 8, 136-143.	3.4	6
222	Opioid Antagonist Treatment of Opioid-Related Disorders. , 2021, , .		1
223	Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder and Retention in Outpatient Substance Use Disorder Treatment. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	11
224	Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108482.	3.2	5
225	Associations Between Copays, Coverage Limits for Opioid Use Disorder Medications, and Prescribing in Medicaid, 2018. <i>Medical Care</i> , 2021, 59, 266-272.	2.4	0
226	Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 12.	2.6	9
227	A preliminary examination of the multiple dimensions of opioid craving. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108473.	3.2	10
228	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	5.9	37
229	Medication for Adolescents and Young Adults With Opioid Use Disorder. <i>Journal of Adolescent Health</i> , 2021, 68, 632-636.	2.5	30
230	Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)". <i>Addiction Science & Clinical Practice</i> , 2021, 16, 15.	2.6	18
231	Gender Differences in Patterns and Correlates of Continued Substance Use among Patients in Methadone Maintenance Treatment. <i>Substance Use and Misuse</i> , 2021, 56, 529-538.	1.4	3
232	Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100728.	1.1	5
233	Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development. <i>BMC Medical Ethics</i> , 2021, 22, 30.	2.4	2
234	Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1406-1413.	0.4	2
235	Case Report: Increasing the Frequency of Intramuscular Naltrexone Administration in a High Risk Patient with Opioid use Disorder. <i>Substance Abuse</i> , 2021, 42, 493-496.	2.3	1
236	Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100704.	1.1	4
237	Incidence and management patterns of alcohol-related liver disease in Korea: a nationwide standard cohort study. <i>Scientific Reports</i> , 2021, 11, 6648.	3.3	2

#	ARTICLE	IF	CITATIONS
238	Recent Advances in the Treatment of Opioid Use Disorder. <i>Current Pain and Headache Reports</i> , 2021, 25, 23.	2.9	2
239	Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX). <i>Journal of Substance Abuse Treatment</i> , 2021, 122, 108183.	2.8	5
240	The opioid crisis and HIV in the USA: deadly synergies. <i>Lancet</i> , The, 2021, 397, 1139-1150.	13.7	68
241	Evaluation of Applications to an Alcohol and Substance Dependence Treatment and Training Centre (AMATEM): Data from Adiyaman Province in 2017. <i>Acibadem Universitesi Saglik Bilimleri Dergisi</i> , 2021, 12, .	0.1	0
242	Medication Treatments for Youth and Young Adults With Opioid Use Disorder. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2021, 59, 9-13.	0.6	0
243	The NIDA clinical trials network: evolving, expanding, and addressing the opioid epidemic. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 28.	2.6	4
244	Impact of Morphine Dependence and Withdrawal on the Reinforcing Effectiveness of Fentanyl, Cocaine, and Methamphetamine in Rats. <i>Frontiers in Pharmacology</i> , 2021, 12, 691700.	3.5	16
245	Treatment of opioid use disorder in primary care. <i>BMJ</i> , The, 2021, 373, n784.	6.0	22
246	A Novel Maintenance Therapeutic for Opioid Use Disorder. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 133-145.	2.5	3
247	Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. <i>International Journal of Drug Policy</i> , 2021, 96, 103283.	3.3	12
248	Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. <i>Journal of Substance Abuse Treatment</i> , 2021, 124, 108292.	2.8	7
249	Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. <i>Addiction</i> , 2021, 116, 3444-3453.	3.3	1
250	Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care?. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2305-2311.	1.8	4
251	Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review. <i>Journal of Dual Diagnosis</i> , 2021, 17, 207-215.	1.2	0
252	Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. <i>American Journal on Addictions</i> , 2021, 30, 433-444.	1.4	4
253	Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention. <i>Journal of Substance Abuse Treatment</i> , 2021, 125, 108306.	2.8	5
254	Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. <i>Contemporary Clinical Trials</i> , 2021, 105, 106394.	1.8	5
255	Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.. <i>Experimental and Clinical Psychopharmacology</i> , 2021, 29, 524-538.	1.8	12

#	ARTICLE	IF	CITATIONS
256	Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, 9, 1557-1567.	3.2	10
257	Chronic Pain, Opioid Use Disorder, and Clinical Management Among Older Adults. <i>Focus (American Tj ETQq1 1 0.784314 rgBT /Over</i>	0.8	4
258	Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. <i>American Journal of Psychiatry</i> , 2021, 178, 660-671.	7.2	18
259	Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 46.	2.6	14
260	Opioid Use Disorder Among Clients of Community Mental Health Clinics: Prevalence, Characteristics, and Treatment Willingness. <i>Psychiatric Services</i> , 2022, 73, 271-279.	2.0	5
261	Optimizing Treatment for Opioid Use Disorder. <i>American Journal of Psychiatry</i> , 2021, 178, 586-587.	7.2	2
262	Cost-effectiveness of Treatments for Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2021, 78, 767.	11.0	45
263	Impacts of Structural Racism, Socioeconomic Deprivation, and Stigmatization on Mental Health. <i>American Journal of Psychiatry</i> , 2021, 178, 575-578.	7.2	10
264	Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. <i>Regional Anesthesia and Pain Medicine</i> , 2021, 46, 840-859.	2.3	51
265	Opioid use disorder: a neglected human immunodeficiency virus risk in American adolescents. <i>Aids</i> , 2021, 35, 2237-2247.	2.2	3
266	The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders. <i>British Journal of Pharmacology</i> , 2023, 180, 879-893.	5.4	7
267	Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. <i>Addiction</i> , 2022, 117, 637-645.	3.3	4
268	Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention. <i>Substance Use and Misuse</i> , 2021, 56, 2160-2170.	1.4	1
269	Health Professionals' Attitudes toward Medications for Opioid use Disorder. <i>Substance Abuse</i> , 2022, 43, 598-614.	2.3	12
270	A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder. <i>Journal of Dual Diagnosis</i> , 2021, 17, 313-332.	1.2	5
271	Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder. <i>Human Psychopharmacology</i> , 2022, 37, e2813.	1.5	2
272	An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108886.	3.2	8
273	Neurocircuitry of Mindfulness-Based Interventions for Substance Use Prevention and Recovery. <i>Current Addiction Reports</i> , 0, , 1.	3.4	1

#	ARTICLE	IF	CITATIONS
274	Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108275.	2.8	20
275	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. <i>JAMA Psychiatry</i> , 2021, 78, 979.	11.0	244
276	Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. <i>American Journal on Addictions</i> , 2021, 30, 453-460.	1.4	2
277	Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108389.	2.8	12
278	Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review. <i>Substance Use and Misuse</i> , 2021, 56, 2181-2201.	1.4	58
279	The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. <i>European Addiction Research</i> , 2022, 28, 56-67.	2.4	3
280	Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108489.	2.8	3
281	Extended-release naltrexone for youth with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108407.	2.8	12
282	Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109077.	3.2	10
283	Optimizing opioid use disorder treatment with naltrexone or buprenorphine. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109031.	3.2	4
284	Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108464.	2.8	10
285	Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108447.	2.8	12
286	Isomorphic Pressures on Jail Diversion: From Serious Mental Illness to Opioid Use Disorder. <i>Prison Journal</i> , 2021, 101, 187-209.	0.7	1
287	Pain and Addiction. , 2021, , 123-135.		0
288	Federally Qualified Health Centers Can Expand Rural Access to Buprenorphine for Opioid Use Disorder in Arizona. <i>Health Services Insights</i> , 2021, 14, 117863292110375.	1.3	1
289	Opioid Use Disorder Pharmacotherapy: A Historical Perspective on How We Practice, and Why. , 2021, , 9-21.		0
290	Medication for the Treatment of Opioid Use Disorder. <i>Current Clinical Psychiatry</i> , 2019, , 89-107.	0.2	1
291	Psychosocial Approaches in the Treatment of Opioid Use Disorders. <i>Current Clinical Psychiatry</i> , 2019, , 109-138.	0.2	4

#	ARTICLE	IF	CITATIONS
292	The Natural History, Clinical Course, and Long-Term Recovery from Opioid Use Disorders. <i>Current Clinical Psychiatry</i> , 2019, , 181-196.	0.2	4
293	Evidence-Based Pharmacotherapies for Alcohol Use Disorder. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1964-1977.	3.0	40
294	Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients. <i>Medical Clinics of North America</i> , 2020, 104, 695-708.	2.5	16
295	Changes in the elimination and resurgence of alcohol-maintained behavior in rats and the effects of naltrexone.. <i>Psychology of Addictive Behaviors</i> , 2020, 34, 10-22.	2.1	7
296	Integrating addiction medicine into rural primary care: Strategies and initial outcomes.. <i>Journal of Consulting and Clinical Psychology</i> , 2019, 87, 952-961.	2.0	12
297	Behavioral strategies to reduce stress reactivity in opioid use disorder: Study design.. <i>Health Psychology</i> , 2020, 39, 806-814.	1.6	6
298	A case report illustrating the effects of repetitive transcranial magnetic stimulation on cue-induced craving in an individual with opioid and cocaine use disorder.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 1-5.	1.8	15
299	Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 449-461.	1.8	20
300	Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa503.	0.9	24
301	Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review. <i>Journal of Addiction Medicine</i> , 2021, 15, 74-84.	2.6	27
302	Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges. <i>Journal of Addiction Medicine</i> , 2021, 15, 454-460.	2.6	10
303	No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. <i>American Journal on Addictions</i> , 2019, 28, 77-85.	1.4	16
304	Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use Disorder. <i>American Journal on Addictions</i> , 2020, 29, 536-542.	1.4	5
305	A Brain-Centric Model of Suicidal Behavior. <i>American Journal of Psychiatry</i> , 2020, 177, 902-916.	7.2	94
306	Opioid Use Disorder in Women and the Implications for Treatment. <i>Psychiatric Research and Clinical Practice</i> , 2021, 3, 3-11.	2.4	33
307	Leveraging machine learning and big data for optimizing medication prescriptions in complex diseases: a case study in diabetes management. <i>Journal of Big Data</i> , 2020, 7, .	11.0	14
308	Improving naltrexone compliance and outcomes with putative pro-dopamine regulator KB220, compared to treatment as usual. <i>Journal of Systems and Integrative Neuroscience</i> , 2020, 6, .	0.6	10
309	Opioid Use Disorder: Diagnosis and Updated Treatment Options. <i>Psychiatric Annals</i> , 2018, 48, 366-371.	0.1	1

#	ARTICLE	IF	CITATIONS
310	Facing Addiction. <i>Psychiatric Annals</i> , 2019, 49, 47-54.	0.1	3
311	Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions. <i>Indian Journal of Psychiatry</i> , 2018, 60, 361.	0.7	8
312	Canadian Guidelines on Opioid Use Disorder Among Older Adults. <i>Canadian Geriatrics Journal</i> , 2020, 23, 123-134.	1.2	20
313	Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. <i>Substance Abuse</i> , 2021, 42, 245-254.	2.3	22
314	Is extended release naltrexone superior to buprenorphine+naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 2569-2578.	2.4	3
315	Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale. <i>Journal of Affective Disorders</i> , 2022, 297, 148-155.	4.1	1
316	Prescribers' satisfaction with delivering medications for opioid use disorder. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 78.	2.2	0
317	The State of Opioid Medication Assisted Treatment (MAT). <i>Journal of Alcoholism and Drug Dependence</i> , 2018, 06, .	0.2	0
318	Killing More than Pain: Etiology and Remedy for an Opioid Crisis. <i>Current Clinical Psychiatry</i> , 2019, , 1-18.	0.2	0
319	Target Population: Treatment-Resistant Opioid Use Disorder and the Role of Therapeutic Communities. , 2019, , 75-85.		0
323	Pilot testing a tool to determine the costs and time associated with community pharmacy-based administration of injectable naltrexone. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 3210-3215.	3.0	1
324	Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis. <i>Journal of Addiction Medicine</i> , 2022, 16, 440-446.	2.6	12
325	Commentary on Ajazi et al (2021) Re-analysis of the X:BOT Trial. <i>Journal of Addiction Medicine</i> , 2022, 16, 382-385.	2.6	4
326	Assessment of the impact of an opioid-specific education series on rates of medication-assisted treatment for opioid use disorder in veterans. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 301-309.	1.0	2
328	The Role of the Defense Attorney in Relation to Biological Interventions As Rehabilitative Strategies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
329	In adult patients with opioid dependence, do naltrexone depot injections lead to better outcomes than buprenorphine?. <i>Evidence-Based Practice</i> , 2020, 23, 23-24.	0.0	0
332	Analysis of psychiatrists' prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States. <i>Trends in Psychiatry and Psychotherapy</i> , 2020, 42, 48-54.	0.8	1
333	Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up. <i>Journal of Substance Abuse Treatment</i> , 2022, 135, 108656.	2.8	1

#	ARTICLE	IF	CITATIONS
334	Opioid Addiction and Treatment. , 2021, , 241-258.		0
335	Suboxone: Rationale, Science, Misconceptions. Ochsner Journal, 2018, 18, 23-29.	1.1	19
336	Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. American Journal of Managed Care, 2018, 24, 526-531.	1.1	9
337	Naltrexone: A History and Future Directions. Cerebrum: the Dana Forum on Brain Science, 2018, 2018, .	0.1	5
338	Medications for Opioid Use Disorder: A Guide for Physicians. Missouri Medicine, 2020, 117, 59-64.	0.3	3
340	Outcomes for patients receiving telemedicine-delivered medication-based treatment for Opioid Use Disorder: A retrospective chart review. Heroin Addiction and Related Clinical Problems, 2021, 23, 5-12.	1.0	4
341	Participants' Treatment Perspectives on a Clinical Trial on the Use of Extended-Release Naltrexone for Substance Use Disorders: Considerations for Future Clinical Research. Journal of Addiction Medicine, 2021, 15, 390-395.	2.6	0
342	Guidance for emergency medicine pharmacists to improve care for people with opioid use disorder. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 214-227.	1.0	0
343	Pain Management Considerations in Patients With Opioid Use Disorder Requiring Critical Care. Journal of Clinical Pharmacology, 2022, 62, 449-462.	2.0	5
344	â€œNot at all what I had expectedâ€™: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. Journal of Substance Abuse Treatment, 2021, , 108667.	2.8	7
345	Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation. American Journal of Drug and Alcohol Abuse, 2022, 48, 217-225.	2.1	2
346	Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. Addiction Science & Clinical Practice, 2021, 16, 67.	2.6	3
347	Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions. Cureus, 2021, 13, e19870.	0.5	4
348	Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications, 2021, 24, 100866.	1.1	3
349	Participantsâ€™ Treatment Perspectives on a Clinical Trial on the Use of Extended-Release Naltrexone for Substance Use Disorders: Considerations for Future Clinical Research. Journal of Addiction Medicine, 2021, 15, 390-395.	2.6	2
350	Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. Journal of the Neurological Sciences, 2022, 432, 120094.	0.6	6
351	Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review. Substance Abuse, 2022, 43, 749-755.	2.3	1
352	Four models of pharmacistâ€œintegrated officeâ€œbased opioid treatment. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 413-421.	1.0	2

#	ARTICLE	IF	CITATIONS
353	Perioperative Opioids, the Opioid Crisis, and the Anesthesiologist. <i>Anesthesiology</i> , 2022, 136, 594-608.	2.5	26
354	Self-Reported Treatment Need and Barriers to Care for Adults With Opioid Use Disorder: The US National Survey on Drug Use and Health, 2015 to 2019. <i>American Journal of Public Health</i> , 2022, 112, 284-295.	2.7	22
355	Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. <i>Drug and Alcohol Dependence</i> , 2022, 233, 109343.	3.2	3
356	Clinical Management of Opioid Withdrawal. <i>Addiction</i> , 2022, 117, 2540-2550.	3.3	12
357	Nonparametric causal mediation analysis for stochastic interventional (in)direct effects. <i>Biostatistics</i> , 2023, 24, 686-707.	1.5	3
358	A likely responder approach for the analysis of randomized controlled trials. <i>Contemporary Clinical Trials</i> , 2022, 114, 106688.	1.8	1
359	HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. <i>Addiction</i> , 2022, 117, 1961-1971.	3.3	10
360	Adjunctive High-Definition Transcranial Direct Current Stimulation in Brain Glutamate-Glutamine and β -Aminobutyric Acid, Withdrawal and Craving During Early Abstinence Among Patients With Opioid Use Disorder on Buprenorphine-Naloxone. <i>Journal of ECT</i> , 2022, 38, 124-132.	0.6	2
361	Understanding and co-managing medication treatment options for opioid use disorder. <i>Internal and Emergency Medicine</i> , 2022, , 1.	2.0	0
362	Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 1493-1513.	1.0	25
363	A Mixed-Methods Evaluation of the Feasibility of a Medical Management-Based Text Messaging Intervention Combined With Buprenorphine in Primary Care. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182210782.	0.9	0
364	Initiating Long-acting Injectable Naltrexone. <i>Journal of Addiction Medicine</i> , 2022, Publish Ahead of Print, .	2.6	1
365	Feasibility and acceptability of collaborative documentation tool for implementing medication-assisted treatment in substance use disorder counseling. <i>Journal of Social Work Practice in the Addictions</i> , 2023, 23, 179-198.	0.7	0
366	Modeling Stimulant and Opioid Co-use in Rats Provided Concurrent Access to Methamphetamine and Fentanyl. <i>Frontiers in Psychiatry</i> , 2022, 13, 814574.	2.6	2
367	Opioid Use Disorder and Racial/Ethnic Health Disparities: Prevention and Management. <i>Current Pain and Headache Reports</i> , 2022, 26, 129-137.	2.9	15
368	Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2022, 17, e0266142.	2.5	13
369	Patient- and Provider-Reported Experiences of a Mobile Novel Digital Therapeutic in People With Opioid Use Disorder (reSET-O): Feasibility and Acceptability Study. <i>JMIR Formative Research</i> , 2022, 6, e33073.	1.4	11
370	Opioid Use Disorder Diagnosis and Management. , 2022, 1, .		5

#	ARTICLE	IF	CITATIONS
371	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 2450-2461.	3.3	3
372	Shifting Focus to Evidence-Based Management of Substance Use Disorders. <i>Annals of Internal Medicine</i> , 2022, , .	3.9	2
373	Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. <i>Addiction</i> , 2022, , .	3.3	4
374	Innovating for real-world care: A systematic review of interventions to improve post-detoxification outcomes for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2022, 233, 109379.	3.2	1
375	Antiretrovirals and Psychotropics: Drug Interactions and Complications. , 2022, , 415-476.		0
376	Baseline and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD. <i>Addiction Biology</i> , 2022, 27, e13112.	2.6	0
377	Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 347-355.	2.1	1
378	Deep brain stimulation for psychiatric disorders and behavioral/cognitive-related indications: Review of the literature and implications for treatment. <i>Journal of the Neurological Sciences</i> , 2022, 437, 120253.	0.6	3
379	Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109469.	3.2	2
380	Negative attitudes about medications for opioid use disorder among criminal legal staff. , 2022, 3, 100056.		5
381	Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. <i>JAMA Network Open</i> , 2022, 5, e2211363.	5.9	12
382	Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2037-2057.	2.8	18
383	Use of Long-Acting Injectable Buprenorphine in the Correctional Setting. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
384	Gender differences among persons entering medication treatment for opioid use disorder in the community. <i>American Journal on Addictions</i> , 2022, 31, 390-395.	1.4	3
385	Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	2.2	3
386	Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes. <i>Journal of Substance Abuse Treatment</i> , 2022, 143, 108830.	2.8	8
387	Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor. <i>MedComm</i> , 2022, 3, .	7.2	5
388	Association Between Interorganizational Collaboration in Opioid Response and Treatment Capacity for Opioid Use Disorder in Counties of Five States: A Cross-Sectional Study. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182211119.	0.9	0

#	ARTICLE	IF	CITATIONS
389	The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State. <i>Addiction Science & Clinical Practice</i> , 2022, 17, .	2.6	2
390	Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release. <i>Journal of Substance Abuse Treatment</i> , 2022, , 108835.	2.8	4
391	Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109565.	3.2	2
392	Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine. <i>Journal of Hospital Medicine</i> , 2022, 17, 744-756.	1.4	13
393	Patientsâ€™ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study. <i>Addiction Science & Clinical Practice</i> , 2022, 17, .	2.6	1
394	Pharmacotherapy of Opioid Use Disorderâ€™ Update and Current Challenges. <i>Psychiatric Clinics of North America</i> , 2022, 45, 335-346.	1.3	3
395	Key considerations for choosing a statistical method to deal with incomplete treatment adherence in pragmatic trials. <i>Pharmaceutical Statistics</i> , 2023, 22, 205-231.	1.3	0
396	Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone. <i>Substance Use and Misuse</i> , 2022, 57, 1732-1742.	1.4	3
397	Under-representation of key demographic groups in opioid use disorder trials. , 2022, 4, 100084.		3
398	A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2022, 239, 109599.	3.2	0
399	Use of long-acting injectable buprenorphine in the correctional setting. <i>Journal of Substance Abuse Treatment</i> , 2022, 142, 108851.	2.8	3
400	Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2022, 142, 108852.	2.8	2
401	Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats. <i>Brain Research Bulletin</i> , 2022, 189, 163-173.	3.0	4
402	Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2022, 239, 109609.	3.2	3
403	Variation in intervention stigma among medications for opioid use disorder. <i>SSM Qualitative Research in Health</i> , 2022, 2, 100161.	1.5	4
404	Facilitators and Barriers to Collaboration between Drug Courts and Community-Based Medication for Opioid Use Disorder Providers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
405	Management of Co-Occurring SUD and Chronic Pain. , 0, , .		0
406	Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder. , 2022, 5, 100100.		1

#	ARTICLE	IF	CITATIONS
407	The Protective Wall of Human Community. <i>Psychiatric Clinics of North America</i> , 2022, 45, 557-575.	1.3	2
408	Opioid agonist treatment for people who are dependent on pharmaceutical opioids. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	6
409	Opioid Use Disorder: Pernicious and Persistent. <i>American Journal of Psychiatry</i> , 2022, 179, 708-714.	7.2	3
410	Evidence-Based Practices for Co-occurring Addiction and Mental Illness. , 2022, , 331-349.		0
411	Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1819-1830.	1.8	0
412	Suicidality as a Predictor of Overdose among Patients with Substance Use Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 6400.	2.4	3
413	Leveraging Accelerometry as a Prognostic Indicator for Increase in Opioid Withdrawal Symptoms. <i>Biosensors</i> , 2022, 12, 924.	4.7	2
414	Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?. <i>American Journal of Health Economics</i> , 2023, 9, 297-330.	3.0	0
415	CDC Clinical Practice Guideline for Prescribing Opioids for Painâ€”United States, 2022. <i>MMWR Recommendations and Reports</i> , 2022, 71, 1-95.	61.1	385
416	Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder. , 2022, 5, 100106.		2
417	Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder. <i>JAMA Health Forum</i> , 2022, 3, e224149.	2.2	5
418	Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials. <i>Addictive Behaviors</i> , 2023, 139, 107589.	3.0	3
419	Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2023, 80, 84.	11.0	2
420	Optimally choosing medication type for patients with opioid use disorder. <i>American Journal of Epidemiology</i> , 0, , .	3.4	0
421	Critical Access Medication for Opioid Use Disorder (MOUD) Treatment Facilities in the Continental United States. , 2022, , 100130.		1
422	The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study. <i>Health and Justice</i> , 2022, 10, , .	2.1	0
423	Prevention of 90-day inpatient detoxification readmission for opioid use disorder by a community-based life-changing individualized medically assisted evidence-based treatment (C.L.I.M.B.) program: A quasi-experimental study. <i>PLoS ONE</i> , 2022, 17, e0278208.	2.5	0
424	The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder. <i>Neuropharmacology</i> , 2023, 225, 109376.	4.1	1

#	ARTICLE	IF	CITATIONS
425	Demographic and socioeconomic correlates to buprenorphine access in pharmacies. Journal of the American Pharmacists Association: JAPhA, 2023, 63, 751-759.	1.5	2
426	Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial. American Journal on Addictions, 2023, 32, 291-300.	1.4	1
427	Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers. , 2023, , 208950.		0
428	Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence, 2023, 243, 109762.	3.2	5
429	Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. JAMA Network Open, 2023, 6, e2252381.	5.9	18
430	Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT. Journal of Addiction Medicine, 0, Publish Ahead of Print, .	2.6	0
431	A pilot study investigating cognitive impairment associated with opioid overdose. Drug and Alcohol Dependence, 2023, 247, 109865.	3.2	0
432	Opioid Kullanma Bozukluu arandirma srecinde aynnetimi: Konfor Kuram ve Nrobilim temelinde bir yaklaam. Hitit Medical Journal; 0, , .	2.0	0
433	Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Addiction Science & Clinical Practice, 2023, 18, .	2.6	2
434	Optimizing buprenorphine training during undergraduate medical education: Medical student feedback and attitudes. American Journal on Addictions, 0, , .	1.4	0
435	Experimental designs for addiction research. , 2023, , 31-53.		0
436	Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. American Journal of Psychiatry, 2023, 180, 386-394.	7.2	3
437	Rethinking the medication management of major depression. Expert Review of Neurotherapeutics, 2023, 23, 331-363.	2.8	1
438	Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study. Contemporary Clinical Trials, 2023, 128, 107148.	1.8	0
439	Untreated substance use disorder affects glycemic control: Results in patients with type 2 diabetes served within a network of community-based healthcare centers in Florida. Frontiers in Public Health, 0, 11, .	2.7	0
440	Treating Adolescents With Opioid Use Disorder: A Medication-Assisted Treatment Approach. Family Journal, 0, , 106648072311644.	1.2	0
441	Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Network Open, 2023, 6, e237036.	5.9	6
442	The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV. , 2023, 7, 100159.		0

#	ARTICLE	IF	CITATIONS
443	Closed-Loop Deep Brain Stimulation for Psychiatric Disorders. <i>Harvard Review of Psychiatry</i> , 2023, 31, 162-171.	2.1	2
444	Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 0, Publish Ahead of Print, .	2.6	0
445	Sex differences in VTA GABA transmission and plasticity during opioid withdrawal. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
446	Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration. <i>Addiction Science & Clinical Practice</i> , 2023, 18, .	2.6	0
447	Alcohol and Drug Use Disorders. , 2023, , 71-84.		0
448	Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder. <i>Psychiatric Services</i> , 2023, 74, 1227-1233.	2.0	2
449	Drug Overdose Prevention: An Exercise in Optimism. <i>American Journal of Psychiatry</i> , 2023, 180, 337-339.	7.2	1
450	High suicidality predicts overdose events among people with substance use disorder: A latent class analysis. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
451	Buprenorphine Prescribing and Dosing Limits: Evidence and Policy Goals. <i>Substance Abuse</i> , 2023, 44, 17-23.	2.3	0
452	Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10888.	4.1	2
453	Acute Pain and Development of Opioid Use Disorder: Patient Risk Factors. <i>Current Pain and Headache Reports</i> , 2023, 27, 437-444.	2.9	3
454	Efficient and flexible mediation analysis with time-varying mediators, treatments, and confounders. <i>Journal of Causal Inference</i> , 2023, 11, .	1.2	0
455	Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone. <i>Heliyon</i> , 2023, 9, e17516.	3.2	0
456	Patient Ineligibility as a Barrier to Participation in Clinical Trials. <i>American Journal of Bioethics</i> , 2023, 23, 83-85.	0.9	2
457	Misclassification of overdose events in the X:BOT study – Authors' reply. <i>Lancet, The</i> , 2023, 402, 527-528.	13.7	1
458	Misclassification of overdose events in the X:BOT study. <i>Lancet, The</i> , 2023, 402, 526-527.	13.7	2
459	Overview about Oral Films in Mental Disorders. <i>Pharmaceuticals</i> , 2023, 16, 1063.	3.8	0
460	Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances. <i>Drug and Alcohol Dependence</i> , 2023, 251, 110926.	3.2	0

#	ARTICLE	IF	CITATIONS
461	The gut microbiome contributes to somatic morphine withdrawal behavior and implicates a TLR2 mediated mechanism. <i>Gut Microbes</i> , 2023, 15, .	9.8	1
462	Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphineâ€naloxone (BUPâ€NX) or extendedâ€release naltrexone (XRâ€NTX) for opioid use disorder. <i>American Journal on Addictions</i> , 0, , .	1.4	0
463	18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies. , 2023, , 209155.		0
464	Pharmacological Treatment of Substance Use Disorders. , 2023, , 1-28.		0
465	The association of medical providersâ€™ attitudes about naloxone and treating people with opioid use disorder and their self-reported low-barrier treatment practices. <i>Addictive Behaviors Reports</i> , 2023, 18, 100514.	1.9	0
466	Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. <i>JAMA Psychiatry</i> , 0, , .	11.0	1
467	Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. <i>JAMA Network Open</i> , 2023, 6, e2329583.	5.9	3
468	Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. , 2023, 154, 209138.		1
469	Access to medication for opioid use disorder supported by telemedicine and healthcare coverage: A web-based survey during the COVID-19 pandemic. <i>Addictive Behaviors Reports</i> , 2023, 18, 100515.	1.9	0
470	Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder. <i>Addiction</i> , 2024, 119, 149-157.	3.3	2
471	Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2023, 49, 618-629.	2.1	0
472	Novel Therapeutic and Program-Based Approaches to Opioid Use Disorders. <i>Annual Review of Medicine</i> , 2024, 75, .	12.2	0
473	The Opioid Overdose Epidemic and Response. , 2023, , .		0
474	Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder. <i>Substance Abuse</i> , 0, , .	2.3	0
475	Pain Medication and Opiate Addiction. , 2023, , 123-129.		0
476	Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2023, 135, 107360.	1.8	0
477	Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges. <i>Frontiers in Psychiatry</i> , 0, 14, .	2.6	0
478	Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. <i>Substance Abuse</i> , 2023, 44, 264-276.	2.3	2

#	ARTICLE	IF	CITATIONS
479	Implementing harm reduction kits in an office-based addiction treatment program. Harm Reduction Journal, 2023, 20, .	3.2	0
480	IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. Pharmacological Research, 2024, 199, 106998.	7.1	0
481	Management of Critically Ill Patients Receiving Medications for Opioid Use Disorder. Chest, 2024, 165, 356-367.	0.8	1
484	Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective. , 2024, 160, 209237.		1
485	Inclusion of Sex and Gender Differences in U.S. State Action Plans for Opioid Use and Opioid Use Disorder. Journal of Women's Health, 0, , .	3.3	0
486	Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort. , 2024, 159, 209281.		0
487	Tapentadol dependence through intravenous injection (â€˜shootingâ€™™) of crushed tablets associated with cutaneous pseudoallergic reactions. BMJ Case Reports, 2023, 16, e257721.	0.5	0
488	Primary care nurse practitioner work environments and emergency department utilization among older adults with substance use disorders in rural areas. , 2024, 157, 209285.		0
489	Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing. , 2024, 160, 209296.		0
490	Opioid use disorder: current trends and potential treatments. Frontiers in Public Health, 0, 11, .	2.7	0
491	The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies. American Journal of Drug and Alcohol Abuse, 2024, 50, 12-26.	2.1	0
492	The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder. Public Health Reports, 0, , .	2.5	0
494	Rethinking Substance Use as Social History: Charting a Way Forward. Journal of General Internal Medicine, 0, , .	2.6	0
495	Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis. Drug and Alcohol Dependence, 2024, 256, 111112.	3.2	0
496	An Approach to Enhancing Medication Treatment for Opioid Use Disorder in the HEALing Communities Study. Psychiatric Services, 0, , .	2.0	0
497	Attitudes toward extended-release naltrexone treatment for opioid use disorder among African Americans. Drug and Alcohol Dependence, 2024, 257, 111260.	3.2	0
498	A Statement on the Pharmacology of Reinstatement: Naltrexone and Relapse to Opioid Seeking. Journal of Pharmacology and Experimental Therapeutics, 2024, 389, 1-4.	2.5	0
499	Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction, 0, , .	3.3	0

#	ARTICLE	IF	CITATIONS
500	Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder. , 2024, 11, 100226.		0
501	Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Network Open, 2024, 7, e242732.	5.9	0
502	Explaining the high mortality among opioid-cocaine co-users compared to opioid-only users. A systematic review. Journal of Addictive Diseases, 0, , 1-11.	1.3	0